Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Intuitive Surgical, a global leader in robotic-assisted surgery, seeks a Principal US Market Access & Reimbursement Director to lead pre-launch reimbursement strategy for Future Forward platforms. You will integrate CPT/HCPCS/ICD-10 coding, Medicare methodologies, and payer economics across teams to secure viable market access.
The role emphasizes strategic judgment and advisory impact, working with Clinical Affairs, Regulatory Affairs, HEOR, and R&D to shape evidence and regulatory paths for
It started with a simple idea: what if surgery could be less invasive and recovery less painful? Nearly 30 years later, that question still fuels everything we do at Intuitive. As a global leader in robotic-assisted surgery and minimally invasive care, our technologies like the da Vinci surgical system and Ion have transformed how care is delivered for millions of patients worldwide.
Were a team of engineers, clinicians, and innovators united by one purpose: to make surgery smarter, safer, and more human. Every day, our work helps care teams perform with greater precision and patients recover faster, improving outcomes around the world.
The problems we solve demand creativity, rigor, and collaboration. The work is challenging, but deeply meaningful because every improvement we make has the potential to change a life.
The Future Forward organization is Intuitive’s advanced concepts group. We explore emerging technologies, prototype next-generation solutions, and build software experiences that shape the future of robotic-assisted surgery.
If you're ready to contribute to something bigger than yourself and help transform the future of healthcare, you'll find your purpose here.
This is a principal-level individual contributor role responsible for US market access and reimbursement strategy for Intuitive's Future Forward growth platforms in the pre-launch period. The Principal, US Market Access & Reimbursement Strategy works upstream and day to day with Clinical Affairs, Regulatory Affairs, HEOR, Medical Affairs, Business Development, and R&D to define the optimal reimbursement pathway for each platform from first-in-human through launch readiness, and to ensure that clinical study design and regulatory strategy are built with that pathway in mind — weighing trade-offs across coding, coverage, and payment options, and advising senior leaders on the risks, sequencing, and decisions needed to reach commercial viability. The role owns the coding, coverage, and payment intelligence that informs both the platforms currently in development and the technologies under evaluation for incubation, licensing, or partnership.
The role is focused on strategy, judgment, and senior-level advisory impact, delivered hands-on rather than through a team. It requires deep working knowledge of the US reimbursement environment: CPT, HCPCS, and ICD-10 coding at a certified coder's level; Medicare coverage and payment methodologies (OPPS, MPFS, IPPS); innovative payment pathways including NTAP, TPT, and NT-APC; provider economics across sites of service, including hospital margin, physician economics, and quality-linked payment programs; and early commercial payer strategy. The successful candidate will have health economics and evidence generation experience, will work independently in the codes and the data, and will present directly to senior management and executives. HEOR builds the economic models and evidence; this role defines what evidence the reimbursement pathway requires, directs that work, and translates it for payers and leadership. The role sits alongside Clinical Affairs and Regulatory Affairs as a standing member of each platform team, contributing to IDE and pivotal study design, endpoint and comparator selection, indication and labeling decisions, and FDA pathway choices wherever they carry coding, coverage, or payment consequences. The US is the primary market; prior international reimbursement or HTA experience is strongly preferred so that US pathway decisions can be read across to global evidence planning.